A low percentage of patients with Type 2 diabetes and decreased adiponectin reach glycemic control

Erika J. Herrera-Oliva ¹, Pablo C. Ortíz-Lazareno ², Anne Santerre ³, Ernesto Prado-Montes de Oca ⁴, María L. Pita-López ¹

¹ Department of Basic Health Sciences, Research Center in Molecular Biology of Chronic Diseases (CIBIMEC), Southern Campus (CUSUR), Universidad de Guadalajara, Ciudad Guzmán, Jal., Mexico; ² Immunology Division, Western Biomedical Research Center, IMSS, Guadalajara, Jal., Mexico; ³ Department of Cellular and Molecular Biology, University Center for Biological and Agricultural Sciences (CUCBA), Universidad de Guadalajara, Zapopan, Jal., Mexico; ⁴ Department of Medical and Pharmaceutical Biotechnology, Laboratory of Regulatory SNPs, Personalized Medicine Laboratory (LAMPER), Guadalajara Unit, Research Center in Technology and Design Assistance of Jalisco State (CIATEJ AC), Consejo Nacional de Ciencia y Tecnología (CONACYT), Guadalajara. Jal., Mexico